share_log

CVS Health | 4: Statement of changes in beneficial ownership of securities-Officer Shah Prem S

CVS Health | 4: Statement of changes in beneficial ownership of securities-Officer Shah Prem S

西維斯健康 | 4:持股變動聲明-高管 Shah Prem S
美股SEC公告 ·  12/03 16:17

Moomoo AI 已提取核心訊息

Shah Prem S, EVP and Group President of CVS Health, completed a stock transaction on 11/30/2024. The transaction involved the sale of common stock, restricted common stock, ESOP common stock, and deferred stock units. Following the transaction, Shah Prem S holds 42,343.677 shares of common stock, 37,057 shares of restricted common stock, 4,968.7985 shares of ESOP common stock, and 3,468.315 deferred stock units. All shares are held directly. This transaction reflects a strategic decision by the executive, impacting his overall shareholding in CVS Health. Investors may consider this action when evaluating the company's stock performance and executive confidence in the company's future prospects.
Shah Prem S, EVP and Group President of CVS Health, completed a stock transaction on 11/30/2024. The transaction involved the sale of common stock, restricted common stock, ESOP common stock, and deferred stock units. Following the transaction, Shah Prem S holds 42,343.677 shares of common stock, 37,057 shares of restricted common stock, 4,968.7985 shares of ESOP common stock, and 3,468.315 deferred stock units. All shares are held directly. This transaction reflects a strategic decision by the executive, impacting his overall shareholding in CVS Health. Investors may consider this action when evaluating the company's stock performance and executive confidence in the company's future prospects.
CVS Health執行副總裁兼集團總裁Shah Prem S於2024年11月30日完成了股票交易。該交易涉及普通股、限制性普通股、ESOP普通股和遞延股票單位的出售。 交易完成後,Shah Prem S持有42,343.677股普通股、37,057股限制性普通股、4,968.7985股ESOP普通股和3,468.315股遞延股票單位。所有股份均直接持有。 該交易反映了該高管的戰略決策,影響了他在CVS Health的總股權。投資者在評估公司的股票表現和高管對公司未來前景的信心時可以考慮這一行動。
CVS Health執行副總裁兼集團總裁Shah Prem S於2024年11月30日完成了股票交易。該交易涉及普通股、限制性普通股、ESOP普通股和遞延股票單位的出售。 交易完成後,Shah Prem S持有42,343.677股普通股、37,057股限制性普通股、4,968.7985股ESOP普通股和3,468.315股遞延股票單位。所有股份均直接持有。 該交易反映了該高管的戰略決策,影響了他在CVS Health的總股權。投資者在評估公司的股票表現和高管對公司未來前景的信心時可以考慮這一行動。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息